B-SMART-Former is proposed, an explainable deep learning framework for predicting interaction types between biotech and small-molecule drugs that integrates ChemBERTa and Morgan molecular fingerprints for small molecules with ProtBERT embeddings for biotech drugs, eliminating the need for similarity-based features while leveraging complementary molecular representations.
Abstract
Drug—drug interactions between biotech and small-molecule drugs play a critical role in medication safety and therapeutic efficacy. However, most existing computational DDI prediction methods focus primarily on interactions between small-molecule drugs, leaving biotech–small-molecule interactions comparatively underexplored. In this study, we propose B-SMART-Former, an explainable deep learning framework for predicting interaction types between biotech and small-molecule drugs. The proposed framework integrates ChemBERTa embeddings and Morgan molecular fingerprints for small molecules with ProtBERT embeddings for biotech drugs, eliminating the need for similarity-based features while leveraging complementary molecular representations. These multimodal features are processed by a hybrid architecture that combines Transformer-based self-attention, residual convolutional learning, and a multi-layer perceptron classifier to capture both global contextual dependencies and local discriminative patterns. The model is formulated as a multi-class classification task and evaluated using stratified 10-fold cross-validation. To improve model transparency, Integrated Gradients is employed as a post-hoc explainability method to identify the molecular features that contribute most strongly to each prediction. Experimental results demonstrate that B-SMART-Former achieves a micro-averaged AUROC of 0.9978 and an AUPR of 0.9682 while relying solely on intrinsic molecular representations, remaining competitive with similarity-based approaches. The proposed framework offers an effective and explainable solution for biotech–small-molecule DDI prediction and provides a practical foundation for future computational drug interaction studies.
This work investigated case studies for interactions with bupropion and ritonavir with integrated gradients and identified molecular regions associated with known CYP-mediated interaction mechanisms.
Andrew Disharoon, Shifi Pasupuleti, Clark Thurston et al.· Frontiers in Drug Safety and...· 0 citations
Accurately predicting synergistic drug combinations remains a critical challenge in computational pharmacology, with important implications for the development of combination therapies in oncology. However, in vitro screening of drug combinations for synergy is both time-consuming and labor-intensive, as the number of...
Sahar Abbasi Rostami, A. Lakizadeh· Discover Artificial Intellig...· 0 citations
This study applies MPS2IT-DTI (Molecule and Protein Sequence to Image Transformer for Drug-Target Interaction), a deep learning framework that represents molecular and protein sequences as images as images using k-mer frequency encoding, enabling convolutional neural networks to capture spatial compositional patterns a...
J. D. de Souza, M. Fernandes, Raquel de Melo Barbosa· Computational biology and ch...· 0 citations
This paper proposes TextDTI, a multimodal framework that simultaneously exploits sequential and structural representations and enhances feature alignment through adversarial learning and contrastive loss, resulting in robust and high-performance DTI prediction.
Jia-Qi Deng, Senyu Tang, Ji-Jun Tang et al.· Journal of Chemical Informat...· 0 citations
DeepGCL is presented, a novel multi-modal framework that leverages multi-view graph contrastive learning to capture latent representations of pocket-drug interactions and their underlying molecular determinants and underscores the effectiveness of multi-view learning paradigms in capturing the multifaceted nature of dr...
Hongmei Wang, Shisen Sun, Mujin Li et al.· IEEE journal of biomedical a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.